.25 mg of semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Novo Nordisk's 25mg daily pill

Time) of Semaglutide tablets Table 6: Statistical results of rybelsus (semaglutide) vs ozempic (semaglutide)

This review focus on GLP-1 and its secretion rhythm as a clue to explore the factors influencing GLP-1 secretion rhythm and the role of exogenous GLP-1-like regulation in GLP-1 rhythm

Acknowledgements This work was supported by grants from the National Natural Science Foundation of China (81930019, 82341076) to Jin-Kui Yang

See our semaglutide guide

Clinical decisions should always be based on the balance of benefits and risks for each patient, taking into account their complete medical history and current health status